6-mercapto-8-(morpholin-1-yl)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile | 889657-42-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 6-mercapto-8-(morpholin-1-yl)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile
• 英文别名: 8-Morpholin-4-yl-6-sulfanylidene-1,3,4,7-tetrahydropyrano[3,4-c]pyridine-5-carbonitrile
• CAS: 889657-42-5
• 化学式: C₁₃H₁₅N₃O₂S
• 分子量: 277.347
• InChiKey: NJZSXIZGELVLDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-mercapto-8-(morpholin-1-yl)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile 在 盐酸 、 氢氧化钾 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  新型抗真菌1,2,3-三嗪的合成与合成孔径雷达研究。

  摘要：

  一系列新的吡啶并噻吩并1,2,3-三嗪具有强大的抗真菌活性。sp。小麦已经被发现。已开发出两种互补的合成此类化合物的途径，并用于有效探索先导化合物周围的构效关系。氧原子结合到分子的侧链中使得化合物的溶解度增加了十倍，同时保留了生物活性。

  DOI：

  10.1016/j.bmcl.2007.06.076
• 作为产物：
  描述：

  四氢吡喃酮 在 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 6-mercapto-8-(morpholin-1-yl)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile
  参考文献：
  名称：

  新型抗真菌1,2,3-三嗪的合成与合成孔径雷达研究。

  摘要：

  一系列新的吡啶并噻吩并1,2,3-三嗪具有强大的抗真菌活性。sp。小麦已经被发现。已开发出两种互补的合成此类化合物的途径，并用于有效探索先导化合物周围的构效关系。氧原子结合到分子的侧链中使得化合物的溶解度增加了十倍，同时保留了生物活性。

  DOI：

  10.1016/j.bmcl.2007.06.076

文献信息

• Synthesis and Biological Activity of Pyrido[3′,2′:4,5]thieno[3,2-<i>d</i>]pyrimidines as Phosphodiesterase Type 4 Inhibitors
  作者：Joan Taltavull、Jordi Serrat、Jordi Gràcia、Amadeu Gavaldà、Míriam Andrés、Mònica Córdoba、Montserrat Miralpeix、Dolors Vilella、Jorge Beleta、Hamish Ryder、Lluís Pagès

  DOI：10.1021/jm100524j

  日期：2010.10.14

  A series of pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidines (PTP) has been synthesized and tested as phosphodiesterase IV inhibitors (PDE4), a target for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Structure−activity relationships within this series, leading to an increase of potency on the enzyme, are presented. The gem-dimethylcycloalkyl moiety fused to the pyridine ring proved

  合成了一系列吡啶并[3'，2'：4,5]噻吩并[3,2- d ]嘧啶（PTP）并作为磷酸二酯酶IV抑制剂（PDE4）进行了测试，这是治疗哮喘和慢性阻塞性疾病的靶标肺部疾病（COPD）。介绍了该系列中的结构活性关系，从而导致了酶效力的提高。为了在酶中获得更高的亲和力，与吡啶环稠合的宝石-二甲基环烷基被证明是支架的关键元素。
• WO2006/58723
  申请人：——

  公开号：——

  公开（公告）日：——
• Antimicrobial Potentiators
  申请人：MICROBIOTIX, INC.

  公开号：US20160075714A1

  公开（公告）日：2016-03-17

  Novel compounds are disclosed having the structure of Formula I: wherein, n is an integer from 1 to 5; X is —CN, —F, —Cl, —Br, —I, —NO 2 ; W is S, SO, SO 2 , O, NH, or NR 5 ; R 5 is alkyl, aralkyl, alkenyl, or alkynyl; Y is O, S; Z is NR 1 R 2 or heterocycloalkyl; R 1 , R 2 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups; R 3 and R 4 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups, and may together form a cyclic structure; and Ar is mono-, di-, or tri-substituted phenyl or heteroaryl, a pharmaceutically acceptable salts thereof. The compounds are potent bacterial efflux pump inhibitors (EPIs). Such compounds are useful to potentiate the antimicrobial activity of antimicrobial compounds such as beta-lactam antibiotics and quinolone antibiotics against Gram-negative bacteria.
• US9540389B2
  申请人：——

  公开号：US9540389B2

  公开（公告）日：2017-01-10
• [EN] ANTIMICROBIAL POTENTIATORS<br/>[FR] POTENTIALISATEURS ANTIMICROBIENS
  申请人：MICROBIOTIX INC

  公开号：WO2014179784A2

  公开（公告）日：2014-11-06

  Novel compounds are disclosed having the structure of Formula I: wherein, n is an integer from 1 to 5; X is -CN, -F, -CI, -Br, -I, -N02; W is S, SO, S02, O, NH, or NR5; R5 is alkyl, aralkyl, alkenyl, or alkynyl; Y is O, S; Z is NR1R2 or heterocycloalkyl; R1, R2 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups; R3 and R4 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups, and may together form a cyclic structure; and Ar is mono-, di-, or tri-substituted phenyl or heteroaryl, a pharmaceutically acceptable salts thereof. The compounds are potent bacterial efflux pump inhibitors (EPIs). Such compounds are useful to potentiate the antimicrobial activity of antimicrobial compounds such as beta-lactam antibiotics and quinolone antibiotics against Gram-negative bacteria.